Anti-IL-13Rα2 therapy promotes recovery in a murine model of inflammatory bowel disease.

ABSTRACT: There continues to be a major need for more effective inflammatory bowel disease (IBD) therapies. IL-13Rα2 is a decoy receptor that binds the cytokine IL-13 with high affinity and diminishes its STAT6-mediated effector functions. Previously, we found that IL-13Rα2 was necessary for IBD in mice deficient in the anti-inflammatory cytokine IL-10. Here, we tested for the first time a therapeutic antibody specifically targeting IL-13Rα2. We also used the antibody and Il13ra2^-/- mice to dissect the role of IL-13Rα2 in IBD pathogenesis and recovery. Il13ra2^-/- mice were modestly protected from induction of dextran sodium sulfate (DSS)-induced colitis. Following a 7-day recovery period, Il13ra2^-/- mice or wild-type mice administered the IL-13Rα2-neutrali

SUBMITTER: Karmele EP 

PROVIDER: S-EPMC6717533 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature